drugset / Trial / NCT02777554
A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the relative bioavailability of apremilast once-daily formulation relative to a twice daily formulation when administered as multiple doses (Part 1), and when administered as a single dose under fasting and fed conditions (Part 2). Information on safety and tolerability will also be obtained.
Timeline
- Start
- 2016-08-17
- Primary completion
- 2016-11-22
- Completion
- 2016-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | — |
| Subject | Apremilast | Small molecule | 75 mg | — |
Indications
No indication recorded.